IQVIA Holdings Inc. (NYSE:IQV) is Lynwood Price Capital Management LP's 8th Largest Position

Key Points

• Lynwood Price Capital Management LP increased its stake in IQVIA Holdings by 38.5% during Q1, now holding 70,200 shares valued at approximately $12.4 million, making it the firm's 8th largest position.
• Major institutional investors are also increasing their stakes in IQVIA, with Pacer Advisors Inc. boosting its holdings by a remarkable 5,036.1% in the same quarter.
• IQVIA reported a profit of $2.81 EPS for the last quarter, surpassing estimates, with a year-over-year revenue growth of 5.3% to reach $4.02 billion.

Lynwood Price Capital Management LP lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 38.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,200 shares of the medical research company's stock after buying an additional 19,500 shares during the quarter. IQVIA comprises about 7.1% of Lynwood Price Capital Management LP's holdings, making the stock its 8th largest position. Lynwood Price Capital Management LP's holdings in IQVIA were worth $12,376,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of IQV. American National Bank & Trust acquired a new position in shares of IQVIA during the first quarter valued at about $26,000. Golden State Wealth Management LLC lifted its position in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA in the first quarter worth about $33,000. ST Germain D J Co. Inc. raised its position in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the period. Finally, GKV Capital Management Co. Inc. bought a new stake in IQVIA in the fourth quarter worth about $39,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research reports. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. William Blair reiterated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Truist Financial lifted their target price on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Robert W. Baird lifted their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, IQVIA has an average rating of "Moderate Buy" and a consensus price target of $228.62.

IQVIA Trading Down 1.8%

NYSE:IQV traded down $3.42 during midday trading on Friday, reaching $182.44. 1,644,130 shares of the stock traded hands, compared to its average volume of 2,321,248. The company has a fifty day moving average of $162.11 and a 200 day moving average of $169.89. The stock has a market capitalization of $31.01 billion, a P/E ratio of 26.40, a PEG ratio of 2.00 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the prior year, the firm posted $2.64 EPS. IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.